Physician profile
Levon Dang
NPI 1760153845
$2,669.18
in general payments reported to CMS, 2019-2025
10 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.28 · 2023: $279 · 2024: $420 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Travel and Lodging: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.67 |
| Travel and Lodging | $1,056.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,675.47 | 2022-2025 | Precision7, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $417.57 | 2024-2025 | Acuvue |
| Biotissue Holdings INC. | $128.40 | 2023 | |
| Glaukos Corporation | $102.15 | 2023-2024 | Radius |
| Sun Pharmaceutical Industries INC. | $99.05 | 2025 | |
| Dompe US, INC. | $95.49 | 2023 | Oxervate |
| Abbvie INC. | $86.73 | 2024 | |
| Bausch & Lomb Americas INC. | $22.41 | 2022 | |
| Kala Pharmaceuticals, INC. | $22.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levon Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.